Low-dose aspirin as treatment for central serous chorioretinopathy
Antonio Caccavale1, Filippo Romanazzi1, Manuela Imparato1, Angelo Negri1, Anna Morano2, Fabio Ferentini11Department of Ophthalmology, Hospital C Cantù, Abbiategrasso, Milan; 2University Eye Clinic, Foundation IRCCS San Matteo Hospital, Pavia, ItalyPurpose: To evaluate the effectivenes...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-08-01
|
| Series: | Clinical Ophthalmology |
| Online Access: | http://www.dovepress.com/low-dose-aspirin-as-treatment-for-central-serous-chorioretinopathy-a4982 |
| _version_ | 1818881491643400192 |
|---|---|
| author | Antonio Caccavale Filippo Romanazzi Manuela Imparato et al |
| author_facet | Antonio Caccavale Filippo Romanazzi Manuela Imparato et al |
| author_sort | Antonio Caccavale |
| collection | DOAJ |
| description | Antonio Caccavale1, Filippo Romanazzi1, Manuela Imparato1, Angelo Negri1, Anna Morano2, Fabio Ferentini11Department of Ophthalmology, Hospital C Cantù, Abbiategrasso, Milan; 2University Eye Clinic, Foundation IRCCS San Matteo Hospital, Pavia, ItalyPurpose: To evaluate the effectiveness of low-dose aspirin for the treatment of central serous chorioretinopathy (CSCR).Patients and methods: Patients with classical or multifocal CSCR were treated with aspirin 100 mg per day orally for 1 month followed by 100 mg on alternate days for 5 months. Treated patients were compared with historic controls consisting of patients with classical or multifocal CSCR previously followed up at our institution.Results: Mean visual acuity in the group treated with aspirin started to improve after the first week of therapy and continued to improve throughout the following 3 months. Visual recovery was slower in the untreated control group than in the treated group and achieved better visual acuity between the first and third month from the onset of the disease. There were no adverse events related to the administration of aspirin.Conclusion: The results indicate that treatment with low-dose aspirin may result in more rapid visual rehabilitation with fewer recurrences in patient with CSCR compared with untreated historic controls. The effectiveness of treatment with aspirin supports our hypothesis regarding the role of impaired fibrinolysis and increased platelet aggregation in the choriocapillaris in the pathogenesis of CSCR.Keywords: central serous chorioretinopathy, aspirin, plasminogen activator inhibitor 1, macula |
| first_indexed | 2024-12-19T15:02:43Z |
| format | Article |
| id | doaj.art-df09e4699ca4414d864fbdb0844326de |
| institution | Directory Open Access Journal |
| issn | 1177-5467 1177-5483 |
| language | English |
| last_indexed | 2024-12-19T15:02:43Z |
| publishDate | 2010-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-df09e4699ca4414d864fbdb0844326de2022-12-21T20:16:31ZengDove Medical PressClinical Ophthalmology1177-54671177-54832010-08-012010default899903Low-dose aspirin as treatment for central serous chorioretinopathyAntonio CaccavaleFilippo RomanazziManuela Imparatoet alAntonio Caccavale1, Filippo Romanazzi1, Manuela Imparato1, Angelo Negri1, Anna Morano2, Fabio Ferentini11Department of Ophthalmology, Hospital C Cantù, Abbiategrasso, Milan; 2University Eye Clinic, Foundation IRCCS San Matteo Hospital, Pavia, ItalyPurpose: To evaluate the effectiveness of low-dose aspirin for the treatment of central serous chorioretinopathy (CSCR).Patients and methods: Patients with classical or multifocal CSCR were treated with aspirin 100 mg per day orally for 1 month followed by 100 mg on alternate days for 5 months. Treated patients were compared with historic controls consisting of patients with classical or multifocal CSCR previously followed up at our institution.Results: Mean visual acuity in the group treated with aspirin started to improve after the first week of therapy and continued to improve throughout the following 3 months. Visual recovery was slower in the untreated control group than in the treated group and achieved better visual acuity between the first and third month from the onset of the disease. There were no adverse events related to the administration of aspirin.Conclusion: The results indicate that treatment with low-dose aspirin may result in more rapid visual rehabilitation with fewer recurrences in patient with CSCR compared with untreated historic controls. The effectiveness of treatment with aspirin supports our hypothesis regarding the role of impaired fibrinolysis and increased platelet aggregation in the choriocapillaris in the pathogenesis of CSCR.Keywords: central serous chorioretinopathy, aspirin, plasminogen activator inhibitor 1, maculahttp://www.dovepress.com/low-dose-aspirin-as-treatment-for-central-serous-chorioretinopathy-a4982 |
| spellingShingle | Antonio Caccavale Filippo Romanazzi Manuela Imparato et al Low-dose aspirin as treatment for central serous chorioretinopathy Clinical Ophthalmology |
| title | Low-dose aspirin as treatment for central serous chorioretinopathy |
| title_full | Low-dose aspirin as treatment for central serous chorioretinopathy |
| title_fullStr | Low-dose aspirin as treatment for central serous chorioretinopathy |
| title_full_unstemmed | Low-dose aspirin as treatment for central serous chorioretinopathy |
| title_short | Low-dose aspirin as treatment for central serous chorioretinopathy |
| title_sort | low dose aspirin as treatment for central serous chorioretinopathy |
| url | http://www.dovepress.com/low-dose-aspirin-as-treatment-for-central-serous-chorioretinopathy-a4982 |
| work_keys_str_mv | AT antoniocaccavale lowdoseaspirinastreatmentforcentralserouschorioretinopathy AT filipporomanazzi lowdoseaspirinastreatmentforcentralserouschorioretinopathy AT manuelaimparato lowdoseaspirinastreatmentforcentralserouschorioretinopathy AT etal lowdoseaspirinastreatmentforcentralserouschorioretinopathy |